Latest Conference Articles

Shan C. Lin, MD, co-research director, Glaucoma Center of San Francisco, speaks on the highlights from his presentation on the latest in the three forms of cyclophotocoagulation commonly used by clinicians.

J. Michael Jumper, MD, a retinal specialist at West Coast Retina (San Francisco, CA), discusses the highlights of his Glaucoma 360 presentation analyzing the impact and lasting effects of intraocular injections and retinal diseases in creating glaucoma as well as the evolving collaboration between retinal and glaucoma specialists.

L. Jay Katz, MD, of the Wills Eye Hospital, Philadelphia, PA, discusses the highlights of his Glaucoma 360 presentation on secondary glaucoma due to intravitreal steroids, and what ophthalmologists can do to minimize the risk of severe visual impairment in patients.

Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.

Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.

The American Society of Cataract and Refractive Surgery has changed the venue for its 2021 annual meeting. The conference will now be held July 23-27 at the Mandalay Bay Convention Center in Las Vegas.

Daniel H. Chang, MD, shares data on a recent study involving a new violet light-filtering chromophore in a preclinical computer simulation testing and randomized clinical study.

Bascom Palmer Eye Institute will hold its 18th annual meeting, titled Angiogenesis, Exudation, and Degeneration 2021, a virtual event set for February 12-13.

Results of a survey among ophthalmologists indicate that patients are receiving fewer examinations — with worsening glaucoma, says S. Fabian Lerner, MD, speaking at the Glaucoma 360 New Horizons Forum.

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.

Joseph F. Panarelli, MD, associate professor of ophthalmology, NYU Langone Medical Center, shares some clinical pearls for managing masquerade syndromes and determining when it is not glaucoma.

Donald L. Budenz, MD, MPH, shares the key takeaways from his Shaffer-Hetherington-Hoskins Lecture, focusing on glaucoma epidemiology, presented during the 2021 Glaucoma 360's 25th Annual Glaucoma Symposium CME.

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.

The traditional treatment for primary angle-closure (PAC) and PAC glaucoma (PACG) is laser peripheral iridotomy (LPI) to facilitate aqueous outflow followed by medical treatment with drops to decrease the intraocular pressure (IOP).

Sunita Radhakrishnan, MD, in a presentation at the 25th annual Glaucoma Symposium at the Glaucoma 360 virtual annual event, noted that concomitant treatment of both glaucoma and dry eye is key.

Robert L. Stamper, MD, discusses the findings of a study analyzing the effects of corneal mechanics on IOP, presented during the virtual Glaucoma 360 meeting.

During the 2021 Glaucoma 360 meeting, Ruth D. Williams, MD, speaks on the highlights and key findings from the EAGLE study, which showed clear lens extraction surgery may be a better initial treatment for some glaucoma patients.

Andrew Iwach, MD, and Adrienne Graves, PhD, co-founders of Glaucoma 360, preview what attendees will experience at the 2021 version of the CME/CE Symposia, Annual Gala, and New Horizons Forum.

Amid a pandemic, the Glaucoma Research Foundation is holding its annual gala online, funding aspirations for a glaucoma-free world with a goal of raising $1 million.

Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.

Robert Ang, MD, discusses highlights of his AAO 2020 presentation on a study analyzing the vIsual outcomes of a small-aperture IOL implantation in patients with a history of post-laser refractive surgery.

Richard Lehrer, MD, speaks on the highlights of a study analyzing the success of SLT after trabecular bypass stenting / phacoemulsification, presented during AAO 2020.

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.

Daniel H. Chang, MD, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the virtual AAO 2020 meeting.

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.